Synairgen plc
28 June 2007
Synairgen plc ('Synairgen' or the 'Company')
Directors' Shareholdings
The Company was informed on 27 June 2007 that Simon Shaw, Non-executive Chairman
of Synairgen, acquired 40,000 ordinary shares of 1p each in the Company ('
Ordinary Shares') at a price of 61 pence per share on 26 June 2007. As a
consequence of this transaction, his holding in the Company equates to 55,400
Ordinary Shares, which represents approximately 0.3 per cent. of the issued
ordinary share capital of the Company. Taking account of his 700,000 Founder
Options (exercisable at nominal value) his total interest represents
approximately 3.5 per cent. of the issued share capital.
The Company was informed on 28 June 2007 that John Ward, Finance Director of
Synairgen, acquired 15,000 Ordinary Shares in the Company at a price of 60.75
pence per share on 28 June 2007. As a consequence of this transaction, his
holding in the Company equates to 22,692 Ordinary Shares, which represents
approximately 0.1 per cent. of the issued ordinary share capital of the Company.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.